Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer

Sanne C. F. A. Huijberts*, Robin M. J. M. van Geel, Rene Bernards, Jos H. Beijnen, Neeltje Steeghs*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)161-174
Number of pages14
JournalFuture Oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Feb 2020

Keywords

  • binimetinib
  • BRAF inhibitor
  • BRAFV600E mutation
  • cetuximab
  • colorectal cancer
  • EGFR inhibitor
  • encorafenib
  • MEK inhibitor
  • metastatic
  • BRAF MUTATION STATUS
  • BRAF(V600E) INHIBITION
  • ANTITUMOR-ACTIVITY
  • DOSE-ESCALATION
  • MEK INHIBITION
  • COLON-CANCER
  • PHASE IB
  • RESISTANCE
  • VEMURAFENIB
  • EGFR

Cite this